Nail Psoriasis: An Updated Review and Expert Opinion on Available Treatments, Including Biologics.


06 Feb 2019 12:09 Ricerca


Nail psoriasis affects 50-79% of patients with skin psoriasis and up to 80% of patients with psoriatic arthritis, and can also represent a negative prognostic factor in individuals with plaque psoriasis.

Treatments for nail psoriasis are limited, as nails are often difficult to treat with topical therapies alone, and relapse is common. Among different systemic agents, secukinumab, a fully human monoclonal antibody targeting interleukin (IL)-17A, is the only antibody supported by a trial specifically conducted in patients with nail psoriasis (the TRANSFIGURE trial) and has the longest follow-up available to date. In this setting, secukinumab is characterized by the highest efficacy at week 16.

This review analysed the different therapeutic options for nail psoriasis, focusing on new treatments that have shown promising results in this field.

Inserito da segreteria SIDeMaST

Approfondimenti

FonteActa Dermatologia Venereologia
Titolo originaleNail Psoriasis: An Updated Review and Expert Opinion on Available Treatments, Including Biologics.
AutoriBardazzi F, Starace M, Bruni F, Magnano M, Piraccini BM, Alessandrini A.
Link fonteLink articolo originale
Argomenti correlati psoriasi ungueale

SIDeMaST è su Facebook

Segui la pagina e diffondi la cultura dermatologica condividendo i contenuti.

Ti è piaciuto questo contenuto?